ArticleCase reports in ophthalmological medicine2026
Management of Mixed Mechanism Glaucoma Secondary to NewColorIris Implant Using an Ab Externo Xen Gel Stent.
Article in Case reports in ophthalmological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Management of Mixed Mechanism Glaucoma Secondary to NewColorIris Implant Using an Ab Externo Xen Gel Stent.Case reports in ophthalmological medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: We present a case of mixed mechanism glaucoma following NewColorIris implant that was successfully treated using an off-label use of Xen Gel Stent. Methods: A retrospective review of the patient's medical records was conducted following the acquisition of informed consent. Results: A 42-year-old female with a history of bilateral cosmetic iris implants presented to the emergency room due to corneal decompensation and a secondary mixed mechanism glaucoma caused by implant iris chafing in her left eye. The patient underwent prosthetic iris implant removal and had persistently elevated intraocular pressures (IOPs) postoperatively. She underwent a subsequent off-label Xen Gel Stent implantation which has successfully controlled her eye pressures without the need for supplementary antiglaucoma medications for 13 months. This off-label use of the Xen Gel Stent helped the patient maintain excellent IOP and satisfied the patient's cosmetic preferences. Conclusion: Xen Gel Stent may be a safe and effective option to treat secondary glaucoma due to cosmetic iris implants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.